Purchase Order 75N91023P00767
Award Date 9/8/23
Potential Completion Date 8/25/24
Potential Value $490K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This firm fixed-price purchase order was awarded by the National Cancer Institute, a component of the National Institutes of Health, to Biofortis, LLC, a for-profit limited liability company. The $28,355.00 contract is for Biofortis to provide software licenses and maintenance support for the Labmatrix clinical and translational research management (CTRM) system. This specialized software platform tracks research information, biospecimens, and results to support data management needs for...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $489,800 firm fixed price purchase order to Biofortis, LLC of Potomac, MD. The contract is for Biofortis Labmatrix software and associated maintenance, development support services, and training. This software will provide the National Cancer Institute Center for Cancer Research with a platform to track research information, biospecimens, and results to support the Center's specialized...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded a $489,805 firm fixed price purchase order to Biofortis, LLC. The contract provides for Biofortis Labmatrix clinical and translational research management software subscriptions, maintenance, and development support services over a base period of performance from August 2021 through August 2022. The original solicitation sought these capabilities on a sole source basis from Biofortis to provide...
- The National Cancer Institute (NCI), part of the National Institutes of Health, awarded a firm fixed-price purchase order to Biofortis, LLC for Labmatrix software subscriptions, maintenance, and development support services in support of the NCI's Center for Cancer Research. The contract, awarded on August 26, 2016, carries a ceiling value of $2.3 million and is designated as a Total Small Business set-aside. The place of performance is Columbia, Maryland. This award includes a de-obligation...
- The National Cancer Institute awarded a $59,900 firm fixed-price purchase order to Caerus US 1 Inc. (operating as Citeline) for renewal of a TrialTrove software license through February 27, 2029. This contract supports oncology research activities conducted by the National Cancer Institute's Cancer Data Science Laboratory and provides access to a curated global clinical trials database with daily updates, bulk data download capabilities, biomarker and genomic data fields, and two concurrent user...
- This is a firm fixed price purchase order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) to Biofortis, LLC, a for-profit limited liability company. The contract is for a one-year software license renewal for the Labmatrix system, which supports data management for cancer and genomics research programs at the NIH's National Cancer Institute and National Human Genome Research Institute. The potential value of the award is $154,750.00. No...
- This is a firm fixed price purchase order award to Biofortis, LLC, a for-profit limited liability company, by the Office of Logistics and Acquisition Operations at the U.S. Department of Health and Human Services. The $79,109.38 contract provides a software subscription, maintenance, development support services, and training for the Labmatrix platform, which supports data management for cancer and genomics research programs at the National Cancer Institute and National Human Genome Research...
- The National Cancer Institute (NCI) awarded a $55,311,391.18 cost-plus-fixed-fee contract to Technical Resources International, Inc. (TRI) for Drug Development Support for the Cancer Therapy Evaluation Program (CTEP). The contract, which runs through September 30, 2022, provides comprehensive clinical research support services to NCI, including clinical trials execution, regulatory support, research operations, and specialized scientific services. TRI, a minority-owned, woman-owned, and Hispanic...
- This is a $111,883,041.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI) to Technical Resources International, Inc. (TRI) for drug development support services for the Cancer Therapy Evaluation Program (CTEP). The contract is not set aside. TRI, a minority-owned, woman-owned, and Hispanic American-owned small business, will provide a wide range of drug development support activities to assist NCI in fulfilling its regulatory responsibilities to the FDA. This includes...
- The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded a $42,551.84 firm fixed price delivery order against the Chief Information Officer Commodities and Solutions (CIO-CS) government-wide acquisition contract to New TECH Solutions, Inc. for software. The delivery order has a period of performance through February 2025 and was awarded on February 15, 2024 without a set aside designation. New TECH Solutions, Inc. will provide the software...